83
Participants
Start Date
September 30, 2014
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2018
Bendamustine and Rituximab
Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Department of Medicine - Hematology, University Hospital Kralovske Vinohrady, Prague
1st Department of Medicine - Hematology, General University Hospital, Prague
Department of Hematology, University Hospital, Pilsen
4th Department of Medicine - Hematology, University Hospital, Hradec Králové
Department of Hematology - Oncology, University Hospital, Brno
Czech CLL Study Group
NETWORK